• 1
    Swinnen L. Post-transplant lymphoproliferative disorders: implications for acquired immunodeficiency syndrome-associated malignancies. J Natl Cancer Inst Monogr 2001;28:3843.
  • 2
    Au WY, Lo CM, Hawkins BR, Ma ES, Lie AK, Kwong YL. Evans' syndrome complicating chronic graft versus host disease after cadaveric liver transplantation. Transplantation 2001;72:527528.
  • 3
    Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997;14:814.
  • 4
    Wagner HJ, Fischer L, Jabs WJ, Holbe M, Pethig K, Bucsky P. Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 2002;74:656664.
  • 5
    Dey B, Sykes M, Spitzer TR. Outcomes of recipients of both bone marrow and solid organ transplants. A review. Medicine 1998;77:355369.
  • 6
    Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)–specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002;99:25922598.
  • 7
    Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus–positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneiccytotoxic T cells. Lancet 2002;360:436442.
  • 8
    Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002;20:12951303.
  • 9
    Au WY, Kwong YL, Lie AK, Ma SK, Liang R. Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation. Hematol Oncol 1999;17:4552.